Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
CytomX Therapeutics Inc (CTMX) is a clinical-stage biopharmaceutical pioneer developing conditionally activated cancer therapies through its probody technology platform. This dedicated news hub provides investors and researchers with essential updates on clinical advancements, strategic collaborations, and therapeutic innovations in oncology.
Access real-time updates on CTMX's probody-based candidates, including antibody drug conjugates and T-cell engagers. The platform centralizes critical developments such as trial milestones, partnership expansions with industry leaders like Astellas and Merck, and financial disclosures - all vital for informed analysis of this innovative oncology company.
Key content categories include clinical program progress, regulatory updates, scientific presentations, and corporate financial results. Each update is curated to highlight how CTMX's tumor-activated therapies aim to improve cancer treatment safety profiles while maintaining therapeutic efficacy.
Bookmark this page for streamlined access to verified CTMX developments. Regularly updated with official press releases and objective reporting, it serves as your primary resource for tracking advancements in conditionally activated cancer immunotherapies.
CytomX Therapeutics (CTMX) has completed its underwritten public offering of 14,285,714 shares at $7.00 per share, generating approximately $93.6 million in net proceeds. The offering was entirely sold by CytomX, which has also granted underwriters a 30-day option to purchase an additional 2,142,857 shares at the same price. The offering was conducted under an SEC registration statement filed in November 2018. The proceeds will be utilized to support the company’s ongoing development of cancer therapies utilizing its Probody technology platform.
CytomX Therapeutics (CTMX) has announced a public offering of 14,285,714 shares at $7.00 each, aiming for gross proceeds of $100 million before expenses. The company intends to allocate the proceeds toward the advancement of its Probody therapeutics pipeline, particularly for ongoing Phase 2 studies of CX-2009 and CX-2029. The offering is set to close around January 25, 2021, subject to customary conditions. This financial move reflects CytomX's commitment to developing innovative cancer treatments through its proprietary technology.
CytomX Therapeutics (CTMX) has announced a public offering of $75 million in common stock, with an additional $11.25 million option for underwriters. Proceeds will fund the advancement of its Probody® therapeutics pipeline, particularly the clinical development of CX-2009 and CX-2029, as well as IND enabling studies for CX-2043 and CX-904. The offering, managed by J.P. Morgan, Cowen, and Piper Sandler, is subject to market conditions and is expected to support ongoing cancer research.
CytomX Therapeutics (Nasdaq: CTMX) announced on January 15, 2021, the granting of stock options to two new employees for a total of 98,000 shares at an exercise price of $7.93, which reflects the closing price on that date. This grant is part of the 2019 Employment Inducement Incentive Plan, approved by the board in August 2020, to attract new talent to the company. CytomX is focused on developing innovative Probody therapeutics for cancer treatment, emphasizing reduced toxicity and increased effectiveness.
CytomX Therapeutics (Nasdaq: CTMX) has announced that its CEO, Sean McCarthy, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 11:40 a.m. ET. Additionally, the company will participate in a pre-recorded presentation through the SternIR Virtual Corporate Access Event from January 11-14, 2021. Webcasts will be available on CytomX’s website, with archived replays accessible for 90 days post-conference. CytomX focuses on developing innovative Probody therapeutics for cancer, partnering with major pharmaceutical companies.
CytomX Therapeutics (Nasdaq: CTMX) has appointed Mani Mohindru, PhD, to its board of directors. Dr. Mohindru, an experienced biotech executive, brings a strong background in finance and corporate strategy, previously serving as CEO of CereXis and CFO at Cara Therapeutics. Her expertise is expected to accelerate the development of CytomX's clinical pipeline, particularly its innovative Probody technology, aimed at creating selective cancer therapies. This leadership change comes as CytomX prepares for multiple critical data releases in 2021.
CytomX Therapeutics (Nasdaq: CTMX) is set to present two posters at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) from December 8-11. The presentations will focus on the clinical activity of CX-2009, a Probody drug conjugate, and its potential in treating advanced breast cancers. Notably, the data highlights the efficacy of CX-2009 alone and in combination with pacmilimab in HER2-non amplified breast cancer. The presentations occur on December 9 at 9:00 AM ET, showcasing CytomX's commitment to innovative cancer treatments.
CytomX Therapeutics (Nasdaq: CTMX) announced that Sean McCarthy, D.Phil., CEO, will participate in two virtual healthcare conferences this November. The Jefferies Virtual London Healthcare Conference is scheduled for November 18, 2020, at 10:15 a.m. ET. Additionally, the 32nd Annual Piper Sandler Virtual Healthcare Conference will occur on November 30, 2020, with a fireside chat available for on-demand viewing starting November 23, 2020, at 10:00 a.m. ET. Webcasts can be accessed on CytomX’s website with archived replays available for 90 days.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) reported its third quarter 2020 financial results, showing revenue of $17.8 million, a 66% increase from the same period in 2019. The company highlighted advancements in its clinical pipeline, including five Probody programs in the clinic, with four in Phase 2 studies. CX-2009 and CX-2029 are among the candidates being developed with initial data anticipated in late 2021. As of September 30, CytomX had $321.1 million in cash and equivalents, reflecting strong financial health.
CytomX Therapeutics (Nasdaq: CTMX) announced the initiation of a Phase 2 expansion study for CX-2029, a Probody drug conjugate targeting CD71, an important cancer target. This study will include various cancer types and is expected to enroll around 25 patients per cohort, focusing on overall response rate (ORR) and safety. The collaboration with AbbVie allows CytomX to earn up to $390 million in milestone payments. Initial data from the study is anticipated in late 2021, further showcasing CytomX's innovative approach to oncology.
FAQ
What is the current stock price of Cytomx Therapeutics (CTMX)?
What is the market cap of Cytomx Therapeutics (CTMX)?
